Ophthalmic composition for glaucoma treatment
US11382887B2 · kind B2 · utility
0Cited by
1References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 21, 2018 |
| Grant date | Jul 12, 2022 |
| Priority date | — |
| Expiry date | Jan 8, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An eye drop composition for treating glaucoma is disclosed. The eye drop composition includes a prostaglandin analogue, a thickening agent, and a solubilizing agent, wherein the thickening agent is carboxymethylcellulose or a salt thereof, and the solubilizing agent is tyloxapol.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.